The K@W Network:
President Trump’s recently announced plan to lower prescription drug prices could benefit consumers in the short run, but it may end up hurting new drug development, experts say.
Is it possible to end all epidemics? Harvard Medical School's Jonathan Quick says there are steps public institutions can -- but don't -- take to protect society.
From a device to prevent glaucoma-related blindness, to a beauty ritual from ancient India, to a competitive penny-wagering mobile game, startups recently battled for $135,000 in cash and prizes.
Serendipity plays a big role in life-science innovation since breakthroughs often are unintended consequences. Yet despite the seeming randomness, this creative process can be managed -- and improved, say experts.
What if a simple nudge could help you make better decisions? A new large-scale experiment headed by two Penn researchers aims to help people develop better exercise habits.
The three heavyweights announced last week that they are joining forces to reduce health care costs for their employees. Will the new model shake up the health care industry?
Traditional Silicon Valley startup models involving venture capital or private equity are missing new markets as health care's evolution speeds up, says one entrepreneur.
Leading pharma companies conspire to keep drug price in the U.S. far higher than a free market would support -- and that also stifles innovation, says the author of a[…]
With debate over the Affordable Care Act likely to take a backseat, here are some key issues facing the U.S. health care sector in 2018.
A merger between CVS and Aetna would create a one-stop model for coordinated care – but would consumers really benefit?
Get Knowledge@Wharton delivered to your inbox every week.